Citius Pharmaceuticals, Inc. (CTXR)
| Market Cap | 179.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.61M |
| Shares Out | 146.13M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | 1.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 226,106 |
| Open | 1.22 |
| Previous Close | 1.23 |
| Day's Range | 1.19 - 1.24 |
| 52-Week Range | 0.83 - 2.01 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 6.80 (+452.8%) |
| Earnings Date | Dec 21, 2022 |
About CTXR
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections followin... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CTXR stock is "Buy." The 12-month stock price forecast is 6.8, which is an increase of 452.85% from the latest price.
News
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application ...
Prescription Drug User Fee Act (PDUFA) target action date is September 28, 2023 CRANFORD, N.J. , Dec. 1, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a l...
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
Net operating losses converted into non-dilutive capital for ongoing R&D programs CRANFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a...
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cuta...
Oral and Poster Presentations to Highlight Clinical Data for I/ONTAK (E7777) Study in Relapsed or Refractory Cutaneous T-cell Lymphoma on December 11, 2022 CRANFORD, N.J. , Nov. 9, 2022 /PRNewswire/ -- ...
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022
CRANFORD, N.J. , Oct. 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-cla...
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022
CRANFORD, N.J. , Oct. 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-clas...
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denil...
CRANFORD, N.J. , Sept. 28, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-cl...
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell De...
I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients University of Pittsburgh dose-ranging study expected to begin in the fourth quarter of 2022 Collaboration mar...
Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute
Leading Center for Autism Education and Research has named Citius and Bartushak the 2022 Honorees for their annual Halloween Gala CRANFORD, N.J. , Sept. 15, 2022 /PRNewswire/ -- Citius Pharmaceuticals, ...
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET CRANFORD, N.J. , Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasd...
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update
$48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023 International sites for Mino-Lok® Phase 3 trial engaged as recruitment accelerates I/ONTAK ...
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment o...
Biologics License Application (BLA) submission planned for the second half of 2022 CRANFORD, N.J. , July 12, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR),...
Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone...
IPO with distribution of shares to Citius shareholders planned for 2H 2022 Citius would retain Mino-Lok and other pipeline assets and continue to trade on Nasdaq (ticker: CTXR) CRANFORD, N.J. , May 25, ...
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-clas...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update
Mino-Lok® Phase 3 trial expanded to include sites outside the U.S.; trial enrollment expected to be completed by end of 2022 Topline results of Phase 3 trial in cancer immunotherapy I/ONTAK consistent w...
3 Reddit Stocks to Buy in May
These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond The post 3 Reddit Stocks to Buy in May appeared first on InvestorPlace. Mor...
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
Additional sites to support trial completion by end of 2022 CRANFORD, N.J. , May 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmace...
Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones
CRANFORD, N.J. , May 3, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class...
Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrh...
Primary endpoint is the reduction in hemorrhoidal symptoms CRANFORD, N.J. , April 26, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharma...
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercia...
Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Ca...
Leonard Mazur named Chairman of the Board of Directors and CEO of Citius Citius co-founder, Myron Holubiak to transition from President & CEO to Executive Vice Chairman of the Board of Directors to buil...
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
Citius Pharmaceuticals Inc (NASDAQ: CTXR) reported topline results from the Phase 3 trial of I/ONTAK (E7777) for persistent or recurrent cutaneous T-cell lymphoma (CTCL). I/ONTAK (E7777) is an engineer...
Shares of Citius jump 18% on new data for experimental lymphoma drug
Shares of Citius Pharmaceuticals Inc. CTXR, -1.60% were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treat...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) fo...
CRANFORD, N.J. , April 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercia...
Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences
CRANFORD, N.J., March 3, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerciali...